Relapsed Acute Myeloid Leukemia
Oncology·MeSH: Leukemia, Biphenotypic, Acute
Prevalence
6.0 / 100K
Incidence
4.3 / 100K/yr
1 drug in development·1 company·5 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| Cytarabine | Syndax Pharmaceuticals Inc (SNDX) |
Frequently asked questions
How many drugs are in development for Relapsed Acute Myeloid Leukemia?
BioSniper tracks 1 drug in development for Relapsed Acute Myeloid Leukemia across 1 company.
How many clinical trials target Relapsed Acute Myeloid Leukemia?
There are 5 clinical trials targeting Relapsed Acute Myeloid Leukemia tracked by BioSniper.
What is the prevalence of Relapsed Acute Myeloid Leukemia?
The estimated prevalence of Relapsed Acute Myeloid Leukemia is approximately 6.0 per 100,000 population.
Deep-dive into Relapsed Acute Myeloid Leukemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis